DE892362C - Process for the recovery of avirulent pathogenic microbes in the manufacture of vaccines - Google Patents

Process for the recovery of avirulent pathogenic microbes in the manufacture of vaccines

Info

Publication number
DE892362C
DE892362C DES5854D DES0005854D DE892362C DE 892362 C DE892362 C DE 892362C DE S5854 D DES5854 D DE S5854D DE S0005854 D DES0005854 D DE S0005854D DE 892362 C DE892362 C DE 892362C
Authority
DE
Germany
Prior art keywords
vaccines
avirulent
manufacture
pathogenic microbes
recovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DES5854D
Other languages
German (de)
Inventor
Andreas Dr Dr Lembke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DES5854D priority Critical patent/DE892362C/en
Application granted granted Critical
Publication of DE892362C publication Critical patent/DE892362C/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Description

Verfahren zur Gewinnung avirulenter pathogener Mikroben bei der Herstellung von Impfstoffen Die aktive Immunisierung von Tieren mit pathogenen Keimen hat für die Gewinnung von Sera für die passive Immunisierung des Menschen z. B. bei der Diphtherie und anderen infektiösen Erkrankungen große Bedeutung erlangt. Das Verfahren der aktiven Immunisierung ist auch zur Gewinnung präzipitierender Sera für die Differentialdiagnose von Mikroben neuerdings höchst bedeutungsvoll geworden.Method of obtaining avirulent pathogenic microbes in manufacture of vaccines The active immunization of animals with pathogenic germs has for the production of sera for the passive immunization of humans z. B. at the Diphtheria and other infectious diseases became very important. The procedure active immunization is also used to obtain precipitating sera for differential diagnosis of microbes has recently become extremely important.

Da man den Versuchstieren oder bei aktiver Immunisierung dem Menschen keine hochvirulenten Keime einspritzen kann, hat man die für das Impfen vorgesehenen Keimau,fschwemmungen bisher durch Einwirkung einer Temperatur von 55 bis 58° C zuvor inaktiviert. Diese Wärmebehandlung führt zur Koagulation und zu einer Denaturierung des Bakterienplasmas und kann zur Gewinnung unspezifischer Sera bzw. zu unvollkommenem Schutz bei aktiver Immunisierung führen. As you can test animals or, with active immunization, humans If you cannot inject highly virulent germs, you have those intended for vaccination So far, germ flooding was caused by exposure to a temperature of 55 to 58 ° C inactivated. This heat treatment leads to coagulation and denaturation of the bacterial plasma and can be used to obtain unspecific or imperfect sera Protection with active immunization.

Erfindungsgemäß wird der Nachteil der Wärmebehandlung bei der Gewinnung avirulenter pathogener Mikroben für Impfstoffe dadurch vermieden, daß die Impfstoffe oder die zu ihrer Herstellung bestimmten Keimaufsdlwemmungen der Einwirkung von Schall schwingungen, insbesondere im Bereich des Ultraschalls, ausgesetzt werden. Bei der Inaktivierung der virulenten Keime gemäß dem Verfahren nach der Erfindung führt der Ultrasthall schon bei Zi.mmertemperatur zwar eine physiXkalische, nicht hingegen eine chemische Veränderung des Bakterienplasmas herbei. Der Ultraschall nimmt also den Bakterien die Vermehrungsfähigkeit, ohne daß die Bakterienzelle sonstige tiefgreifentde Schädigungen erleidet. Die durch das Impfen-erstrebte Wirkung bleibt erhalten, ohne daß es zu ungewollten Schädigungen infolge Vermehrung der Bakterien kommt. Die durch Ultraschallinaktivierung gewonnenen präzipitierenden Sera zeichnen sich, wie praktische Versuche erwiesen haben, durch hohe Spezifität und Wirkungskonzentration aus. According to the invention, there is the disadvantage of heat treatment during extraction Avirulent pathogenic microbes for vaccines avoided by having the vaccines or the germ suspensions intended for their production by the action of Sound vibrations, especially in the area of ultrasound, are exposed. at the inactivation of the virulent germs according to the method According to the invention, the ultrasonic reverberation leads to a physiXcal, does not, however, bring about a chemical change in the bacterial plasma. The ultrasound thus takes away the ability of the bacteria to multiply without the bacterial cell doing anything else suffers profound damage. The effect sought by the vaccination remains obtained without causing unwanted damage as a result of the proliferation of bacteria comes. Draw the precipitating sera obtained by ultrasound inactivation as practical tests have shown, through high specificity and concentration of action the end.

Claims (1)

PATENTANSPRUCH: Verfahren zur Gewinnung avirulenter pathogener Mikroben bei der Herstellung von Impfstoffen, dadurch gekennzeichnet, daß die Impfstoffe oder die zu ihrer Herstellung bestimmten Keimaufschwemmungen der Einwirkung von Schall schwingungen, insbesondere im Bereich des Ultraschalls, ausgesetzt werden. PATENT CLAIM: Process for obtaining avirulent pathogenic microbes in the manufacture of vaccines, characterized in that the vaccines or the suspensions of germs intended for their production by the action of Sound vibrations, especially in the area of ultrasound, are exposed.
DES5854D 1944-06-06 1944-06-06 Process for the recovery of avirulent pathogenic microbes in the manufacture of vaccines Expired DE892362C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DES5854D DE892362C (en) 1944-06-06 1944-06-06 Process for the recovery of avirulent pathogenic microbes in the manufacture of vaccines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DES5854D DE892362C (en) 1944-06-06 1944-06-06 Process for the recovery of avirulent pathogenic microbes in the manufacture of vaccines

Publications (1)

Publication Number Publication Date
DE892362C true DE892362C (en) 1953-10-05

Family

ID=7471652

Family Applications (1)

Application Number Title Priority Date Filing Date
DES5854D Expired DE892362C (en) 1944-06-06 1944-06-06 Process for the recovery of avirulent pathogenic microbes in the manufacture of vaccines

Country Status (1)

Country Link
DE (1) DE892362C (en)

Similar Documents

Publication Publication Date Title
DE2817891A1 (en) ND VACCINE AND METHOD FOR THE PRODUCTION THEREOF
DE892362C (en) Process for the recovery of avirulent pathogenic microbes in the manufacture of vaccines
Costigan Effectiveness of hot hypochlorites of low alkalinity in destroying Mycobacterium tuberculosis
Shaughnessy et al. Treatment of wounds inflicted by rabid animals
Cruickshank Epidemiology of some skin infections
DE1617545A1 (en) Antigen-free vaccines
Peluffo Stability of Vi Antigen of Salmonella typhi.
Dalldorf et al. Resistance induced by vaccinia virus to pertussis infection in mice
Mitchell AMYCOTIC DERMATOSES SIMULATING RINGWORM AND EROSIO. INTERDIGITALIS BLASTOMYCETICA
Fairbrother et al. Further Observations on the Immunization of the Horse with the Poliomyelitis Virus
CH629962A5 (en) METHOD FOR PRODUCING A VACCINE AGAINST CAT PANLEUKOPENIA.
DE859195C (en) Process for the manufacture of vaccines
DE424197C (en) Process for the production of a nutrient medium for influenza bacilli and for the production of vaccines from them
DE2340911A1 (en) TETANUS ANTIGEN AND PROCESS FOR ITS PRODUCTION
DE521739C (en) Process for the manufacture of vaccines
DE330348C (en) Process for the preparation of a gonorrhea agent
DE1174016B (en) Process for the production of a live vaccine against foot and mouth disease
DE627813C (en) Process for the production of a disinfecting agent for protecting the skin against infections and for healing skin diseases
Varea Torresi et al. Comparative study between the use of Brix-3000 and the rotational conventional technique against tooh decay
DE2702634A1 (en) Feline panleukopenia virus attenuated vaccine prodn. - by passaging through cat kidney cells and felid or mustelid permanent cell line
US2268955A (en) Bacterial product and bacteria strain and process of producing the same
DE914177C (en) Process for the preparation of solutions for blood substitutes, blood fluid substitutes, plasma and serum substitutes
DE394735C (en) Process for the production of vaccines or immune sera, with the exception of those against cancer
DE384635C (en) Process for the preparation of vaccines from human tuberculosis bacilli or bovine tubercle bacilli for protection against tuberculosis
DE349806C (en) Process for the sterilization of healing serums, vaccines and similar fluids